Taro Pharmaceutical Industries (NYSE:TARO) was upgraded by equities research analysts at ValuEngine from a “sell” rating to a “hold” rating in a research report issued on Thursday.
A number of other research analysts have also commented on the company. HC Wainwright reaffirmed a “buy” rating and issued a $115.00 price objective on shares of Taro Pharmaceutical Industries in a report on Monday, December 10th. Zacks Investment Research raised Taro Pharmaceutical Industries from a “sell” rating to a “hold” rating in a report on Thursday, October 11th.
Shares of NYSE TARO opened at $94.62 on Thursday. Taro Pharmaceutical Industries has a one year low of $76.93 and a one year high of $121.23. The firm has a market capitalization of $3.73 billion, a price-to-earnings ratio of 15.31 and a beta of 0.40.
Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. Marshall Wace LLP acquired a new stake in shares of Taro Pharmaceutical Industries during the 3rd quarter worth $689,000. BlueMountain Capital Management LLC grew its holdings in shares of Taro Pharmaceutical Industries by 31.7% during the 3rd quarter. BlueMountain Capital Management LLC now owns 9,271 shares of the company’s stock worth $911,000 after purchasing an additional 2,230 shares in the last quarter. Renaissance Technologies LLC grew its holdings in shares of Taro Pharmaceutical Industries by 15.3% during the 3rd quarter. Renaissance Technologies LLC now owns 331,000 shares of the company’s stock worth $32,537,000 after purchasing an additional 44,000 shares in the last quarter. Citadel Advisors LLC acquired a new stake in shares of Taro Pharmaceutical Industries during the 3rd quarter worth $4,417,000. Finally, GSA Capital Partners LLP acquired a new stake in shares of Taro Pharmaceutical Industries during the 3rd quarter worth $315,000. 10.38% of the stock is currently owned by institutional investors.
About Taro Pharmaceutical Industries
Taro Pharmaceutical Industries Ltd., a science-based pharmaceutical company, engages in the development, manufacture, and marketing of pharmaceutical products in the United States, Canada, Israel, and internationally. It offers prescription and over-the-counter pharmaceutical products focusing on primary areas, including topical creams and ointments, liquids, capsules, and tablets in the dermatological and topical, cardiovascular, neuropsychiatric, and anti-inflammatory therapeutic categories.
Further Reading: What is a put option?
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Taro Pharmaceutical Industries Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Taro Pharmaceutical Industries and related companies with MarketBeat.com's FREE daily email newsletter.